{"id":538259,"date":"2021-09-14T17:33:03","date_gmt":"2021-09-14T21:33:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/"},"modified":"2021-09-14T17:33:03","modified_gmt":"2021-09-14T21:33:03","slug":"syneos-health-acquires-studykik","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/","title":{"rendered":"Syneos Health Acquires StudyKIK"},"content":{"rendered":"<h2>\nAcquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and Diversity<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">MORRISVILLE, N.C., Sept.  14, 2021  (GLOBE NEWSWIRE) &#8212; Syneos Health<sup>\u00ae<\/sup> (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JArijBnaerqjp1Yhss89XuuSmmDd_jbubkqRXh2MPkgzFL1TEHKAKOaY9BJ6OnFPVrBA3Ugefy-UVyIT_mJ0Yg==\" rel=\"nofollow noopener\" target=\"_blank\">StudyKIK<\/a>, a leading technology-enabled clinical trial recruitment and retention company. Accelerating product development by better connecting patients, sites and communities, the acquisition boosts Syneos Health\u2019s ability to deliver technology-enabled, insight-powered solutions. Customer benefits include accelerated patient enrollment and retention, extensive patient population-based insights, improved site, sponsor and physician experiences and reduced patient burden.<\/p>\n<p>Launched in 2014 as a global network of patient-focused communities, StudyKIK and its technology platform has demonstrated improved quality and accelerated enrollment timelines in certain clinical trials by up to 94% and reduced enrollment start-up times by up to 75%. In addition, StudyKIK provides eConsent, Telemedicine video calling, Phone Pre-Qualifications, and Patient Retention application solutions. The company manages over 1,000 indication-specific patient community groups and has enrolled more than 5,400 protocols supporting over 3,800 research sites across the globe. The platform encompasses more than 6 million patients through social media, speeding access to patients who traditionally would not have participated in clinical trials.<\/p>\n<p>Aligned to Syneos Health\u2019s patient, site and community strategic focus, StudyKIK adds new scale and capabilities to improve the patient journey while optimizing data science and behavioral insights to support commercialization for products. This acquisition further expands Syneos Health\u2019s portfolio of patient-direct, technology-enabled solutions complementing the recent acquisition of Illingworth Research Group, a provider of mobile research nursing services, and the company\u2019s recently announced technology partnerships with <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QRFly26EQV4ZZ9pDj0291t7UyCcO-b8UE_sjJUlD34vVU1kwBm6th5ih2FqWIbOrxZsPpmDY52yYfuo7wbtbobbB0HPdt3S0EIq7a5m6MpuGEE1sf7hlz8mVoYTAq79eHhexC0guPimSPGIucBhyBvE6SffzHzdQFijchX4Sq_N1eVCW4K-zA0akFkRHFJm5GzeqCXgx1t8PjIWQXAU8YA==\" rel=\"nofollow noopener\" target=\"_blank\">Ride Health<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ClbR8GzX5Jp8fviEM-aRyUePYYOT5hzuf2FDWPrImixqynmAWN8dBHP2SfbhA50MCG7XFY04LP-QaoEZ8D61Rac1JVLvNG6IFjpY4P-8hlRXFfXPXQEMclu-AT20OBfADUYjozT7-leol39XcmiHZH35nLC0kIaizex8gFF2Xq2EwYeD_88Td_tpLEVMuWw3U_qq9hUo-acEMdNRCQr2EYwiUPj-XzDjixaF5F-SfHE=\" rel=\"nofollow noopener\" target=\"_blank\">Science37<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MlVb9IPBNocKIOy8tebOQnlrqIkGhuiHwswvTn5H3a0OperV9bhtGF266i0acgskBW7RfJ3SHEvHaqk845snN9i0iLiUTT_DCaV5FPuObaiHj7qEK_mQlSKg1ZUM-YzbszT5iktLAQtsSZ9UGgk_CcqVMPEWGaFh9gmLl4P1sah5s-yWIkVQ6bwl8BF8aPWdikhSC3shTRXnVJWYg6-RAQ==\" rel=\"nofollow noopener\" target=\"_blank\">Medable<\/a>.<\/p>\n<p>\u201cStudyKIK\u2019s patient-first focus, combined with their innovative enterprise platform, helps to advance our goal of bringing best-of-breed insights and technology-enabled solutions to biopharma customers, sites and patients,\u201d said Alistair Macdonald, CEO, Syneos Health. \u201cWe are excited to welcome the StudyKIK team to the Syneos Health family. Together we\u2019ll accelerate product development by improving stakeholder experiences, realizing efficiencies in patient recruitment, engagement, improved access and diversity.\u201d<\/p>\n<p>The acquisition of StudyKIK is also strategic to growing the Syneos Health Dynamic Assembly<sup>\u00ae<\/sup> network \u2013 an open ecosystem of best-of-breed data and technology collaborators \u2013 designed to strategically address the nuances of unique customer engagements. This \u201calways on\u201d innovation environment realizes synthesized insights across the product lifecycle.<\/p>\n<p>\u201cStudyKIK\u2019s mission has always focused on making a difference in the world by bringing new treatments to people faster through education and innovative, industry-leading tools and services that make access to clinical trials easier,\u201d said Matt Miller, CEO and Co-Founder, StudyKIK. \u201cJoining the Syneos Health family further supports this mission. Together, we will offer the industry an integrated solution to quicken patient recruitment, increase site support and efficiencies, and guide clinical trial participants through every step of their clinical trial journey.\u201d<\/p>\n<p>\n        <strong>About StudyKIK<\/strong><br \/>\n        <br \/>StudyKIK is a patient recruitment and retention technology company that was founded on building patient communities to increase awareness for clinical trials. Servicing over 3,600 research sites, StudyKIK supports patient recruitment, patient retention, eConsent Solutions, Telemedicine Video Calling, and study companion mobile applications to expedite clinical trials. They have addressed the clinical trial patient recruitment and retention problem by building the technology solutions needed for research sites and pharmaceutical companies to access, manage, and communicate with high-quality patients in real-time.<\/p>\n<p>\n        <strong>About Syneos Health<\/strong><br \/>\n        <br \/>Syneos Health<sup>\u00ae<\/sup> (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 27,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers\u2019 delivery of important therapies to patients.<\/p>\n<p>To learn more about how we are Shortening the Distance From Lab to Life<sup>\u00ae<\/sup>, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cKTSD5UVFKpdQA69YGciez-sdXBqqL6nr6AgbYIslB2pduLO3tZxbLmuxkPGdmyH352yh9EGEg7nVax9nok1zVSaqe19Mz3AVc6pL7-xRu4=\" rel=\"nofollow noopener\" target=\"_blank\">syneoshealth.com<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eivciRfRf1MQ0K0LERhNh5PJrEdVXe1LnUraui10thD_NLlzsW3F0OXVYIPXodDtWGue1_fGGYqp1u_3jEJy_j0L-C2KbTv8Cqmqrxv2AOU=\" rel=\"nofollow noopener\" target=\"_blank\">subscribe to our podcast<\/a>.<\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Investor Relations Contact:<\/strong><br \/>\n            <br \/>Ronnie Speight<br \/>Senior Vice President, Investor Relations<br \/>+1 919 745 2745<br \/><a href=\"mailto:Investor.Relations@syneoshealth.com\" rel=\"nofollow noopener\" target=\"_blank\">Investor.Relations@syneoshealth.com<\/a><\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Press\/Media Contact:<\/strong><br \/>\n            <br \/>Gary Gatyas<br \/>Executive Director, External Communications<br \/>+1 908 763 3428<br \/><a href=\"mailto:gary.gatyas@syneoshealth.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>gary.gatyas@syneoshealth.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZThlZjRjNjItMzUyMy00YmUxLWFjNmUtMzFkNjk3NDI5NDEzLTEwMTU4MjI=\/tiny\/Syneos-Health-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and Diversity MORRISVILLE, N.C., Sept. 14, 2021 (GLOBE NEWSWIRE) &#8212; Syneos Health\u00ae (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of StudyKIK, a leading technology-enabled clinical trial recruitment and retention company. Accelerating product development by better connecting patients, sites and communities, the acquisition boosts Syneos Health\u2019s ability to deliver technology-enabled, insight-powered solutions. Customer benefits include accelerated patient enrollment and retention, extensive patient population-based insights, improved site, sponsor and physician experiences and reduced patient burden. Launched in 2014 as a global network of patient-focused communities, StudyKIK and its technology platform has demonstrated improved quality and accelerated enrollment timelines in certain clinical trials &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Syneos Health Acquires StudyKIK&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-538259","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Syneos Health Acquires StudyKIK - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syneos Health Acquires StudyKIK - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and Diversity MORRISVILLE, N.C., Sept. 14, 2021 (GLOBE NEWSWIRE) &#8212; Syneos Health\u00ae (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of StudyKIK, a leading technology-enabled clinical trial recruitment and retention company. Accelerating product development by better connecting patients, sites and communities, the acquisition boosts Syneos Health\u2019s ability to deliver technology-enabled, insight-powered solutions. Customer benefits include accelerated patient enrollment and retention, extensive patient population-based insights, improved site, sponsor and physician experiences and reduced patient burden. Launched in 2014 as a global network of patient-focused communities, StudyKIK and its technology platform has demonstrated improved quality and accelerated enrollment timelines in certain clinical trials &hellip; Continue reading &quot;Syneos Health Acquires StudyKIK&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-14T21:33:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Syneos Health Acquires StudyKIK\",\"datePublished\":\"2021-09-14T21:33:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/\"},\"wordCount\":672,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/\",\"name\":\"Syneos Health Acquires StudyKIK - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=\",\"datePublished\":\"2021-09-14T21:33:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syneos-health-acquires-studykik\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syneos Health Acquires StudyKIK\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syneos Health Acquires StudyKIK - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/","og_locale":"en_US","og_type":"article","og_title":"Syneos Health Acquires StudyKIK - Market Newsdesk","og_description":"Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and Diversity MORRISVILLE, N.C., Sept. 14, 2021 (GLOBE NEWSWIRE) &#8212; Syneos Health\u00ae (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of StudyKIK, a leading technology-enabled clinical trial recruitment and retention company. Accelerating product development by better connecting patients, sites and communities, the acquisition boosts Syneos Health\u2019s ability to deliver technology-enabled, insight-powered solutions. Customer benefits include accelerated patient enrollment and retention, extensive patient population-based insights, improved site, sponsor and physician experiences and reduced patient burden. Launched in 2014 as a global network of patient-focused communities, StudyKIK and its technology platform has demonstrated improved quality and accelerated enrollment timelines in certain clinical trials &hellip; Continue reading \"Syneos Health Acquires StudyKIK\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-14T21:33:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Syneos Health Acquires StudyKIK","datePublished":"2021-09-14T21:33:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/"},"wordCount":672,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/","name":"Syneos Health Acquires StudyKIK - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=","datePublished":"2021-09-14T21:33:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTk1OSM0NDA1MzI5IzIwMDQyNDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syneos-health-acquires-studykik\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Syneos Health Acquires StudyKIK"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=538259"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538259\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=538259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=538259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=538259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}